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Abstract
MicroRNAs (miRNAs) are implicated in numerous physiologic and pathologic
processes, such as the development of resistance to chemotherapy. Determining
the role of miRNAs in these processes is often accomplished through measuring
miRNA abundance by polymerase chain reaction, sequencing, or microarrays. We
have developed a system for the large‐scale monitoring of dynamic miRNA activity
and have applied this system to identify the contribution miRNA activity to the
development of trastuzumab resistance in a cell model of HER2+ breast cancer.
MiRNA activity measurements identified significantly different activity levels
between BT474 cells (HER2+ breast cancer) and BT474R cells (HER2+ breast cancer
cells selected for resistance to trastuzumab). We created a library of 32 miRNA
reporter constructs, which were delivered by lentiviral transduction into cells, and
miRNA activity was quantified by bioluminescence imaging. Upon treatment with the
bioimmune therapy, trastuzumab, the activity of 11 miRNAs were significantly
altered in parental BT474 cells, and 20 miRNAs had significantly altered activity in
the therapy‐resistant BT474R cell line. A combination of statistical, network and
classification analysis was applied to the dynamic data, which identified miR‐21 as a
controlling factor in trastuzumab response. Our data suggested downregulation of
miR‐21 activity was associated with resistance, which was confirmed in an additional
HER2+ breast cancer cell line, SKBR3. Collectively, the dynamic miRNA activity
measurements and analysis provided a system to identify new potential therapeutic
targets in treatment‐resistant cancers.
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1 | INTRODUCTION
Targeted therapy for the treatment of breast cancer has significantly
improved the expected outcomes for patients with specific disease
subtypes. For example, the humanized HER2 antibody, trastuzumab,
developed as a therapy for the treatment of HER2+ breast cancers, has
led to tremendous progress in the treatment of the 20% of breast cancer
patients with amplified HER2 (Cobleigh et al., 1999; Romond et al., 2005;
Slamon et al., 2001). Yet despite these advances, limitations remain,
namely the development of resistance to targeted therapy (Nahta, Yu,
Hung, Hortobagyi, & Esteva, 2006). Many mechanisms for resistance to
trastuzumab have been suggested, including PTEN activation (Nagata
et al., 2004), cyclin E overexpression (Scaltriti et al., 2011), and PI3K3CA
pathway activation (Berns et al., 2007), among others (Gong et al., 2011;
Gottesman, 2002; Valabrega, Montemurro, & Aglietta, 2007). While
progress has been made as for new therapeutic strategies for
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trastuzumab‐resistant breast cancer, the precise mechanisms and
systems responsible for treatment failure are active and critical areas
of investigation.
One increasingly studied mechanism for resistance is altered
expression of microRNA (miRNA) in the resistant cells. MiRNA is a
class of small noncoding RNA that act as inhibitors of translation.
MiRNAs recognize complementary sequences in the 3′ untranslated
region (3′ UTR) and recruit Argonaut to the mRNA, causing
degradation. MiRNA acts as a regulator for gene expression and
can buffer against changes in endogenous promoter activity
(Filipowicz, Bhattacharyya, & Sonenberg, 2008; Jonas & Izaurralde,
2015; Nilsen, 2007). MiRNA can act as an oncogene due to its
regulatory role and have been associated with metastasis (Ma,
Teruya‐Feldstein, & Weinberg, 2007; Tavazoie et al., 2008; Yan et al.,
2008) and epithelial–mesenchymal transition (Burk et al., 2008;
Chang et al., 2011; Wellner et al., 2009). MiRNA abundance is often
altered in cancer and has therefore been suggested as a prognostic
indicator (Lu et al., 2005; Volinia et al., 2006). MiRNAs 21, 125, 145,
and 155 were recently identified as significantly dysregulated in
breast cancer and correlated with clinical outcome (Iorio et al., 2005).
Additionally, several studies have linked dysregulation of the
abundance of miRNAs such as miR‐21 (Gong et al., 2011), miR‐125
(Luo et al., 2017), miR‐210 (Jung et al., 2012), or miR‐375 (Ye et al.,
2014) to differential sensitivity to trastuzumab therapy in HER2+
cancer, indicating an essential role for miRNA activity in mediating
the response to targeted therapy.
Currently, miRNAs associated with treatment resistance have
been almost exclusively identified by their abundance relative to
healthy tissues. However, tracking the abundance of miRNA may
overlook critical mechanistic data as for the effects of the
differential activity of these molecules. To this end, methods to
track abundance of miRNA do not always correlate with miRNA
activity (Mullokandov et al., 2012), indicating that abundance‐based
methods may not accurately delineate the impact of a particular
miRNA on the physiology of the cancer cell. Furthermore, monitor-
ing the dynamics of the miRNA may identify crucial mechanistic
information or time points that is associated with miRNA function.
New methods to dynamically track miRNA activity in treatment‐
resistant cancers could provide crucial insights currently lacking in
the field of miRNA‐mediated drug resistance.
In this report, we developed a system to monitor miRNA
regulatory dynamics in trastuzumab‐resistant HER2+ breast cancer,
to identify potential therapeutic targets and mechanisms that
mediate resistance. The system for monitoring miRNA activity was
based on adopting a technology termed TRACER (TRanscriptional
ACtivity CEll aRray), which had been used to track the dynamic
activity of transcription factors (Bernabé et al., 2016; Decker et al.,
2017). TRACER utilizes a parallel reporter assay to probe the
dynamics of transcription factor activity during treatment. These
reporters consist of a luciferase gene whose expression is driven by a
transcriptional response element. Luciferase measurements on living
cells provide a dynamic measure of activity within the cells during
treatment, which can be applied to a wide variety of culture systems
or reporter constructs. We have previously used TRACER to identify
transcriptional targets in PARP inhibitor‐resistant BRCA‐mutated
breast cancer (Decker et al., 2017), as well as to determine
transcriptional regulators of ErbB2‐mediated (HER2‐mediated) on-
cogenesis in breast cancer (Weiss et al., 2014). Herein, we developed
a library of miRNA reporter constructs, which consists of constructs
encoding for the luciferase gene with a miRNA recognition sequence
in the 5′ region. Active miRNA can bind to the luciferase mRNA at
the recognition site and lead to degradation of the luciferase mRNA,
decreasing luminescence and providing a dynamic measurement of
changes in miRNA activity. We characterized the miRNA activity
in cells treated with trastuzumab to examine and identify the
differential activity associated with resistance. A previously devel-
oped computational pipeline was used to determine key miRNA
from the dynamic multivariate data, which were then validated
experimentally.
2 | MATERIALS AND METHODS
2.1 | Cells and reagents
BT474 and SKBR3 cells were sourced from the American Type Cell
Culture repository. BT474 cells were maintained in Dulbecco’s
modified Eagle’s medium supplemented with 10% fetal bovine serum.
SKBR3 cells were maintained in McCoy’s 5A media supplemented
with 10% fetal bovine serum. Media was replaced every 3 days and
cells were passaged after they became 80% confluent. A trastuzu-
mab‐resistant cell line (BT474R) was established by continuous
culture of the parental BT474 line in 10 μg/ml trastuzumab for
greater than 6 months, as previously described (Scaltriti et al., 2011).
2.2 | MiRNA inhibitor assay
Cell viability was analyzed by MTS assay (Sigma, St. Louis, MO). Cells
(1,500–3,000) were plated in each well of a 96‐well tissue culture plate
with 100 μl of medium. The next day, cells were transfected with either
miR‐21 Power Inhibitor (Exiqon, Vedbaek, Denmark) or random Power
Inhibitor control inhibitor using JetPrime (PolyPlus, Illkirch, France). After
24 hr, the media was replaced with 100 μl of fresh media containing
10 μg/ml trastuzumab or vehicle control, as indicated, and the cells were
grown for 3 days. Stock trastuzumab was prepared in deionized water
and stock miRNA inhibitor was prepared in TE buffer. At the end of the
treatment period, 10 μl of MTS solution was added to each well, the cells
were incubated at 37°C for 1 hr, and absorbance was read at 490nm.
Data are presented as a percentage of the control cells cultivated under
the same conditions or the absorbance of the wells. Two‐way analysis of
variance and Tukey’s test for multiple comparisons was used to
statistically evaluate differences between groups.
2.3 | Lentivirus
Lentivirus was produced by co‐transfecting HEK‐293T cells with
previously described lentiviral packaging vectors (pMDL‐GagPol,
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pRSV‐Rev, and pIVS‐VSV‐G; Dull et al., 1998) and lentiviral vectors
using JetPrime (PolyPlus). After 48 hr, supernatants were collected
and cell debris was spun down and removed. Viruses were
concentrated using PEG‐it (Systems Biosciences, Palo Alto, CA) and
resuspended in phosphate buffered saline. Viral titer was measured
using a qPCR Lentivirus Titration Kit (ABM, Richmond, BC, Canada).
2.4 | MiRNA activity arrays
MiRNA activity reporters consist of a single miRNA binding site
cloned into the 3′ UTR of a phosphoglycerate kinase (PGK)
promoter‐driven firefly luciferase. Firefly luciferase was chosen as
the reporter because of the linear relationship between lumines-
cence and enzyme abundance over several orders of magnitude.
Activity of the miRNA binding at the recognition site of a target
mRNA leads to degradation and an overall reduction of signal from
that reporter. MiRNA sequences were sourced from miRbase
(Kozomara & Griffiths‐Jones, 2013), with the exact complementary
sequence to the miRNA used for the reporter. Reporter sequences
were cloned between the NheI and XhoI recognition sites in the
pmirGlo vector from Promega (Madison, WI). This reporter was
excised from the original backbone using BglII and XhoI and cloned
between the BamHI and XhoI sites of the pCS‐CG third generation
lentiviral vector (Miyoshi, Blömer, Takahashi, Gage, & Verma, 1998).
Dynamic miRNA activity was measured for two cell lines. BT474
cells overexpress HER2 and are sensitive to trastuzumab. A resistant
derivative of these cells (BT474R) was used as a model for acquired
resistance to trastuzumab. Activity was measured for 32 different
miRNAs during 48 hr of treatment with 10 μg/ml trastuzumab.
Measurements acquired at several time points (0, 2, 4, 6, 8, 24, and
48 hr) allowed both initial differences between cell types as well as
differences in response to trastuzumab treatment to be elucidated
from the data.
All cell types were transduced with 10 MOI of each miRNA
activity‐reporting lentivirus. Transduced cells were then seeded on a
96‐well plate with at least three technical replicates of each
condition. All reporters were repeated with at least n = 3 for
biological replicates. Two days after cell seeding, luciferase activity
was measured using an IVIS Spectrum (Caliper Life Sciences,
Hopkinton, MA). The 2‐day period is sufficient time for ensuring
lentiviral gene expression. After changing media, cells were treated
with 10 µg/ml of trastuzumab, and the luciferase activity was
measured for 48 hr. A blank reporter with no miRNA binding site
was used as a control. Thus, all other miRNA activity was normalized
with respect to blank activity and represented by miRNA/blank ratio.
MiRNA reporters start at a high luminescence and are dimmer as the
miRNA is more active and therefore degrading the luciferase mRNA.
As such, less light emission correlates to higher miRNA activity.
2.5 | Statistical analysis
Activity levels for different miRNAs were normalized to a blank
reporter with the corresponding treatment. We performed background
subtraction and loss normalization to correct for systematic noise. All
normalized miRNA activity levels were log2 transformed. Results of
experiments are presented as the mean ± standard error unless
otherwise indicated. Differences in means were evaluated by fitting
an empirical hierarchical Bayesian linear model using the limma R
package (Smyth, 2005). p‐Values were adjusted using the false
discovery rate correction (Benjamini & Hochberg, 1995). A p‐value
less than 0.05 was considered to be statistically significant.
2.6 | Classification analysis
Principal components analysis (PCA) and partial least‐squared discrimi-
nant analysis (PLS‐DA) were performed to identify multivariate
combinations of factors and their time course that would separate
the different conditions. Both analyses were performed using the
mixOmics package in R (Rohart, Gautier, Singh, & Le Cao, 2017). Each
individual 96‐well plate included only a subset (10–16 of 32) of the
measured miRNAs. Since both PCA and PLS‐DA require the full
complement of measured factors, we used randomly sampled individual
biological replicates to generate 1,000 simulated experiments contain-
ing one biological replicate of every miRNA for PCA and PLS‐DA. Data
were normalized to blank reporter control and untreated control within
an experiment before sampling, leaving three equivalent groups:
Treated BT474 (HCP_BT474), treated BT474R (HCP_BT474R), and
untreated BT474/BT474R (NT). Individual experiments were variance
scaled to standardize all data before multivariate analysis.
2.7 | Network analysis
Network analysis of miRNA activity measurements was carried out
using a modified version of NTRACER, which has been described
previously (Bernabé et al., 2016). As with the classification analysis,
biological replicate data was sampled to create 50 sets of complete
measures for each run of the network analysis. A total of 500 runs
was performed. Normalized activity measurements were variance
scaled and an initial network topology inferred through several
different techniques: Linear methods (PLSR [Mevik & Wehrens,
2007], similarity index [Siletz et al., 2013], linear ordinary differential
equations based on TIGRESS [Haury, Mordelet, Vera‐Licona, & Vert,
2012]), and nonlinear methods (ARACNE [Margolin et al., 2006], CLR
[Faith et al., 2007], MRNET [Meyer, Kontos, Lafitte, & Bontempi,
2007]). Features were selected from the top 10% of edges for each
inference method at each set of time points based on the relevant
score for each inference technique. Possible connections between
miRNAs were assigned a score of one if they were in the top 10% at
least once in the set of time points. The results of each inference
method summed between runs, and the final 10% of summed edges
for the entire experiment were calculated after the conclusion of
500 runs of the inference code. Network edges were further pared by
including only edges that were inferred through multiple inference
methods to ensure high‐quality connections in the final model.
Networks were visualized and analyzed for eigenvector centrality
using the R package iGraph (Csardi & Nepusz, 2006).
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2.8 | Selection of relevant miRNA
We adapted a previously published method for identifying transcrip-
tion factors that mediate drug resistance to this study of miRNA
activity (Decker et al., 2017). Three different analysis methods were
used to score miRNAs, with a total of four components leading to the
score. These methods were selected to account for univariate
differences between treatments, multivariate scoring and networked
connections between factors. Statistical analysis using limma was
used to compare treated BT474R cells to (a) untreated BT474R cells
and (b) treated parental BT474 cells. Reporters were scored either a
one (significant) or a zero (not significant) based on this analysis.
Second, the network analysis from NTRACER was used to score the
reporters based on their centrality to the network. Eigenvector
centrality awarded scores between 0 and 1 based on how central
the reporter was to the network. Finally, variable importance in
projection (VIP) scores from the PLS‐DA were used to measure the
importance of each reporter within the multivariate context of these
experiments. The maximum VIP score for each individual time point
was used and scaled so 1 was the maximum value. The top scoring
factor using these criteria was selected for further analysis.
3 | RESULTS
3.1 | Large‐scale dynamic miRNA activity
measurement
We initially investigated miRNA activity dynamics in two related cell
lines that overexpress HER2 yet have different responses to
trastuzumab: BT474 (parental) and BT474R (resistant). A total of 32
miRNAs were selected based on their previous association with drug
sensitivity in cancer. These two cell lines had significantly different
miRNA activity patterns at baseline, with a trend toward a higher
number of active miRNAs in the treatment‐sensitive cells. Two miRNAs
were initially “active” in BT474R cells (miR‐92 and miR‐200a), which
was observed as less luminescence compared with a blank control
(p < 0.05), while 19 miRNAs were “active” in the parental BT474 cell line
(Figure 1a,b). The most active of these miRNAs, in the BT474 cell line,
were miR‐21, miR‐23b, and miR‐32. Among the miRNAs that were
significantly active in the BT474 cells, two were significantly different
from BT474R activities at baseline, miR‐20 and miR‐32.
We next monitored dynamic miRNA activity in response to
trastuzumab treatment in both cell lines. Significant alterations in
miRNA activity were observed in both cell lines over 48 hr of
treatment (Figure 2). A total of 11/32 (34%) miRNAs were significantly
altered in BT474 cells (p < 0.05), with miR‐100, miR‐145, and miR‐221
having the most substantial changes (p < 0.01). With respect to the
resistant cell line (BT474R), a total of 20/32 (63%) miRNAs had
significantly altered activity in response to trastuzumab. A total of 15
of these miRNAs were altered beyond the p < 0.01 threshold, with
miR‐21, miR‐335, miR‐200a, miR‐32, miR‐373, and miR‐210 showing
the most significant alterations (p < 1e − 7). Hierarchical clustering of
miRNA dynamics between the two cell lines demonstrated six broad
clusters of miRNAs with similar activity between the two cell types.
The two most unique clusters contained one factor (miR‐21) and two
factors (miR‐7 and miR‐18a).
Connections between miRNAs based on their activity were
subsequently inferred through implementation of a compilation of
network inference tools (Bernabé et al., 2016). Two networks were
inferred, one for trastuzumab response in cells that respond to the drug
(BT474; Figure 3a) and one for cells that were resistant to the drug
(BT474R; Figure 3b). These networks utilized the aggregate connections
inferred between miRNAs for each time point to produce connections
and central hub nodes for each network. Hub nodes were identified as
those whose eigenvector centrality score was in the top 10% of all
nodes. Hub nodes were interpreted as important to the response to
trastuzumab, and not necessarily as direct targets of trastuzumab
treatment. Both networks had similar hub nodes at miR‐20 and miR‐21.
Responsive cells had additional hubs at miR‐92 and miR‐183, while
sensitive cells had hubs at miR‐9 and miR‐99b. These miRNAs
represented hubs based on their influence at one or more times in
the network, as inferred by one or more of the methods used to create
the consensus network.
3.2 | Identification of controlling miRNA
We utilized both unsupervised (PCA) as well as supervised (PLS‐DA)
classification methods to determine a combination of variables that
F IGURE 1 Static, initial microRNA (miRNA) activity
measurements in (a) trastuzumab sensitive (BT474) and (b) resistant
(BT474R) cells. Data is presented as log normalized difference
between miRNA reporter and a blank control. Negative numbers
indicated increased miRNA activity. Error bars represent standard
error
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F IGURE 2 Dynamic microRNA (miRNA) activity in both BT474 (sensitive) and BT474R (resistant) cell lines during treatment with
trastuzumab. Data is presented as log 2 normalized difference between miRNA reporter and a blank control. Brackets indicate groups identified
through hierarchical clustering
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separated BT474, BT474R and pooled normalized untreated controls.
PCA was used to confirm the accuracy of separating the cells into three
distinct types (Figure 4a). Two principal components were calculated,
with PC1 explaining 20% of the sample variance and PC2 explaining 11%
of the variance. Three broad groups of samples were found, which agreed
with the three measurements that were used for the analysis (normalized
untreated, treated BT474, treated BT474R). All conditions were normal-
ized to the experimental control, and as such, both types of cells had
similar values for the control and can be considered as one group for this
analysis. A correlation circle of the top 10 variables (Figure 4b) had three
clusters of factors and time points. miR‐7, miR‐18a, and miR‐135b formed
one cluster, while miRs 200a and 373 formed another along PC1. miRs
145, 146, 183, and 195 formed a cluster on PC2, with miR‐23b forming
solitary point as well. These variables were all‐time point specific, which
can be seen in the variable name (Figure 4b).
PLS‐DA was used to identify a multivariate signature for the
time‐course changes in miRNA activity in the sensitive and resistant
cell lines and also to identify how these cells lines differed from
untreated control cells (Figure 5). We have previously demonstrated
that this method provided superior classification for dynamic
transcription factor activity data (Decker et al., 2017), and as such
used this method to identify the linear combinations of miRNAs that
best delineated treated and untreated sensitive and resistant cells.
The time‐course PLS‐DA classified the cells into three groups
(untreated aggregate, treated BT474, treated BT474R) with 98.9%
accuracy from 10‐fold cross validation using two components with
10 selected variables for each loading vector. Different factors were
found to be highly loaded in LV1 (X axis) compared with LV2 (Y axis;
Figure 5b,c). LV1 delineated resistant from sensitive and untreated
cells. miR‐21 after 48 hr was the highest loaded factor in LV1, with
F IGURE 3 Network analysis for (a) BT474 and (b) BT474R cells over 48 hr treatment with trastuzumab. Yellow nodes are hubs identified by
eigenvector centrality
F IGURE 4 (a) Principal components analysis of time‐course miRNA activity data. Data from separate partial experiments was randomly
sampled to create 1,000 complete “experiments” for use analysis. (b) Correlation circle plot of selected activity measurements for the PCA
model. miRNA: microRNA; PCA: principal component analysis
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BT474 cells treated with trastuzumab having the highest level of
activity. LV2 also delineated treated and untreated BT474 cells, with
miR‐150 after 4 hr as the highest loaded factor. VIP scores for the
selected factors were also calculated (Figure 5d). These scores
correspond to the relative estimated importance of each variable in
the PLS‐DA model. For the PLS‐DA model associated with these
experiments, the VIP scores were similar for both LV1 and LV2, with
the highest score assigned to miR‐21.
We subsequently tested the ability of our miRNA activity
measurements to select relevant factors associated with trastuzumab
resistance, using a method that combined statistical, classification, and
network analyses (Decker et al., 2017). We scored our miRNAs based
on their statistical significance between trastuzumab‐resistant cells
and untreated controls and treated responsive cells, centrality in the
network analysis and importance in the PLS‐DA model. This
scoring system had a maximum possible value of 4, with the highest
score factor selected for analysis; using these criteria, miR‐21 was
identified as the leading factor associated with trastuzumab resis-
tance (Figure 6a). Initial activity measurements indicated increased
miR‐21 activity in BT474 cells relative to BT474R cells, with both
lines having a decrease in activity in response to therapy. Based on
the results with this model system, we hypothesized that miR‐21 is a
regulator of trastuzumab sensitivity, and specifically that inhibiting
miR‐21 activity will decrease the sensitivity to trastuzumab. This
hypothesis was tested by transfection of a miR‐21 inhibitor into
SKBR3 cells, which served as a distinct model of HER2+ breast cancer,
unrelated to the study cells from which the hypothesis was derived.
Transfection with a miR‐21 inhibitor resulted in a 17% decrease in
proliferation of SKBR3 cells relative to a random inhibitor control
(Figure 6b). Both cells transfected with a miR‐21 inhibitor, as well as
those cells transfected with a random control, were sensitive to
trastuzumab; however, the effect of the drug differed significantly
between treatment groups (Figure 6c). The relative effect of adding
trastuzumab to the system was significantly decreased in the
presence of the miR‐21 inhibitor compared to cells transfected with
a random control inhibitor (17% decrease for miR‐21 inhibitor
condition compared with 40% in the control, p < 0.001). Collectively,
treatment with trastuzumab resulted in decreased proliferation;
however, inhibition of miR‐21 reduced the impact of trastuzumab
and thus contributed to the sensitivity to trastuzumab.
F IGURE 5 (a) PLS‐DA plot separating bootstrapped samples from untreated, treated BT474 and BT474R cells. (b) VIP scores across for
model. Similar scores were measured in both LVs. (c) Loadings in LV1. (d) Loadings in LV2. Colors indicate cell line/treatment with highest
activity level. Ellipses in (a) represent 95% confidence intervals. PLS‐DA: partial least‐squared discriminant analysis; VIP: variable importance in
projection
DECKER ET AL. | 2619
4 | DISCUSSION
MiRNA has been the focus of intense study as both a biomarker and
a therapeutic target (Pereira, Rodrigues, Borralho, & Rodrigues,
2013). In this report, we have used a new method, a miRNA activity
array, to identify drug resistance mechanisms associated with HER2+
breast cancer. We generated a library of miRNA reporters with 3′
UTRs that are exact matches to endogenous miRNAs from miRbase
(Kozomara & Griffiths‐Jones, 2013), which provides reporting for
activity with maximum sensitivity and specificity. Our miRNA activity
array expands upon our previous work developing a transcription
factor activity array (Bellis et al., 2011; Bernabé et al., 2016; Decker
et al., 2017) to measure the dynamic regulome in living cells. Both
arrays utilize activity measurements of regulatory factors to provide
a unique perspective on the regulome of the cell that can be missed
through other techniques. Quantitative polymerase chain reaction
and sequencing methods, the most commonly used methods to
elucidate essential miRNAs in biological processes, are both
expensive and often do not correlate well to the activity level of
the miRNA (Mullokandov et al., 2012). Systems to report activity,
therefore, have the potential to more effectively identify miRNAs
that may serve as effective therapeutic targets. Our dynamic activity
platform offered both a means to simultaneously quantify the activity
of many relevant miRNAs, and implement the time‐course of the
dynamic activity to identify key factors controlling treatment
response.
Our studies identified downregulation of miR‐21 activity as
associated with the intracellular response to trastuzumab and
development of resistance. The identification of decreased miR‐21
activity as contributing to trastuzumab‐resistant HER2+ breast cancer
was performed using an updated analysis pipeline previously
developed to recognize transcriptional targets of resistance to PARP
inhibitors. This method combined statistical, classification and net-
work analyses to identify factors that are consistently important in
both the resistant phenotype, as well as the response to treatment in
responsive and unresponsive cells. Time‐course data provided a
superior platform for both classification (Antonucci, De Rosa, Giusti, &
Cuzzolin, 2015; Park, Koo, Kim, Sohn, & Lee, 2008; Robinson, Glonek,
Koch, Thomas, & Davies, 2015) and network analysis, (Bar‐Joseph,
Gitter, & Simon, 2012; Bernabé et al., 2016) when compared with
static data, which allowed the multiple techniques to converge on a
single factor, miR‐21.
Importantly, each method of analysis offered complementary
information that was not available from a single technique. Statistical
analysis provided a list of differential activities induced by the
resistant phenotype, as well as treatment with trastuzumab. These
measurements lack the multivariate context in which the different
phenotypes can be distinguished. Network analysis provided a means
to identify controlling hubs within the network and, when placed in
the context of multivariate classification, to identify which factors
that were essential in controlling treatment response. This report has
updated the analysis pipeline to include a numerical score for each
F IGURE 6 (a) Relative importance scores from statistical, network and classification identify miR‐21 as important in trastuzumab resistance.
(b, c) Proliferation assay for vehicle and trastuzumab‐treated SKBR3 cells. (b) Effect of miR‐21 on baseline proliferation of SKBR3 cells. (c) Effect
of trastuzumab on proliferation in vehicle and inhibitor‐treated cells. **p < 0.01 and ***p < 0.001. miR‐21: microRNA‐21
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factor, thus reducing bias that may be introduced in interpreting the
results and providing a solid foundation for further experimentation.
This particular study found miR‐21 had the highest score. The next
highest scoring factors, miR‐99b and miR‐92, have both been
implicated in cancer aggressiveness and prognosis (Kang et al.,
2012; Nilsson et al., 2012; Si et al., 2013; Wei et al., 2013).
Specifically, miR‐92a has been suggested as a partner to miR‐21 as a
biomarker for primary breast cancer (Si et al., 2013), supporting that
this scoring method can identify relationships between factors
associated with breast cancer, yet additional studies would be
required to identify the precise mechanisms by which these factors
may promote resistance to trastuzumab.
The relevance of miR‐21 to HER2‐targeted therapy was
identified by its unique dynamics, centrality in the network, and
ability to delineate sensitive and resistant cells in the multivariate
analysis. The identification of miR‐21 as a controlling factor for
therapeutic response and resistance is supported by the literature
for a number of different drugs and cancer types. MiR‐21 activity has
been implicated in the onset of drug resistance, and was reported to
mediate resistance to treatments including cisplatin (Yang et al.,
2013), gefitinib (Shen et al., 2014), and sorafenib (He et al., 2015).
Specific to breast cancer, miR‐21 abundance has been suggested as a
biomarker for therapeutic response, (Müller et al., 2014; Si et al.,
2013) and may confer resistance to trastuzumab (De Mattos‐Arruda
et al., 2015; Gong et al., 2011). We observed an initial decrease in
miR‐21 activity in both study cell types upon treatment with
trastuzumab, followed by divergent activity patterns: Sensitive cells
showed increased miR‐21 activity while resistant cells maintained
relatively low levels of activity (Figure 2). These results may be
explained by the role of miR‐21 in cell cycle regulation. Trastuzumab
is considered to be cytostatic rather than cytotoxic to cells in vitro
(Scaltriti et al., 2011; Vu & Claret, 2012), and as this therapy is
antiproliferative (and is also why proliferation‐based assays, such as
the MTS used in this study, are appropriate). MiR‐21 activity
inhibition should increase expression of miR‐21 target genes, such
as the tumor suppressor PTEN, which would lead to a decrease
in proliferation. We did indeed observe decreased proliferation in
miR‐21 inhibitor‐treated SKBR3 cells, a second trastuzumab respon-
sive cell line, compared with vehicle‐treated cells, consistent with
the proposed hypothesis. Furthermore, inhibiting miR‐21 activity
decreased the relative response to trastuzumab, which would be
expected if trastuzumab acts in part through inhibition of miR‐21
activity.
The regulome of the cell ultimately determines the cell fate, and
disruption of the calibrated regulatory mechanisms of the cell can
ultimately lead to oncogenic transformation. We advanced our
previously described TRACER technology to encompass dynamic
monitoring of miRNA activity and used this array to investigate the
dynamics of miRNA activity in HER2+ breast cancer to identify
potential miRNA‐mediated mechanisms for resistance. Both super-
vised and unsupervised classification could identify treated and
untreated cells from both the resistant and responsive phenotypes,
consistent with our previous observations using this method
(Decker et al., 2017). Downregulation of miR‐21 activity was
identified through the multivariate analysis as a potential driving
factor for the resistant phenotype in HER2+ breast cancer cells. This
hypothesis was confirmed by inhibiting the activity of miR‐21, results
that extended to an independent model of HER2+ breast cancer. This
tool for large‐scale analysis of miRNA activity could be applied to
numerous systems to identify the function of miRNA in cell fate
determination, and these miRNAs may serve as either biomarkers or
therapeutic targets.
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